VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The von Hippel-Lindau tumor suppressor protein (pVHL) is crucial for degrading hypoxia-inducible factors (HIFs).
• Mutations in pVHL cause von Hippel-Lindau (VHL) disease, leading to various tumors, including pheochromocytomas.
• The molecular basis for pheochromocytoma development in VHL disease remains unclear.

Purpose of the Study:

• To biochemically analyze pVHL mutant proteins associated with type 2C VHL disease (pheochromocytoma only).
• To investigate the structural and functional consequences of type 2C mutations on pVHL and the CBC(VHL) complex.

Main Methods:

• Biochemical analysis of recombinant pVHL-ElonginC-ElonginB complexes.
• Assessment of protein stability and proteolytic susceptibility using in vitro methods.
• Nuclear Magnetic Resonance (NMR) spectroscopy to analyze protein structure.
• Cellular studies in human cell lines to evaluate complex stability and pVHL levels.

Main Results:

• Type 2C mutations induced significant structural perturbations in pVHL, reducing its stability and increasing susceptibility to proteolysis.
• NMR analysis revealed dramatically altered spectra for mutant pVHL complexes.
• In cell lines, these mutations destabilized the CBC(VHL) ubiquitin ligase complex and lowered cellular pVHL levels.

Conclusions:

• Type 2C VHL disease-associated pVHL mutations cause substantial structural defects.
• These structural defects likely impair both HIF-1/2alpha regulation and other pVHL functions, contributing to pheochromocytoma pathogenesis.